Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer.

about

Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q47450308

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pharmacokinetic drug evaluatio ...... of non-small cell lung cancer.

@en

Pharmacokinetic drug evaluatio ...... of non-small cell lung cancer.

@nl

type

Item

label

Pharmacokinetic drug evaluatio ...... of non-small cell lung cancer.

@en

Pharmacokinetic drug evaluatio ...... of non-small cell lung cancer.

@nl

prefLabel

Pharmacokinetic drug evaluatio ...... of non-small cell lung cancer.

@en

Pharmacokinetic drug evaluatio ...... of non-small cell lung cancer.

@nl

P1476

Pharmacokinetic drug evaluatio ...... of non-small cell lung cancer

@en

P2093

Antonio Rossi

http://www.w3.org/2001/XMLSchema#string

Concetta Di Micco

http://www.w3.org/2001/XMLSchema#string

Cristiano Carbonelli

http://www.w3.org/2001/XMLSchema#string

Gerardo Sanpaolo

http://www.w3.org/2001/XMLSchema#string

Giuseppe Palomba

http://www.w3.org/2001/XMLSchema#string

Lucia Anna Muscarella

http://www.w3.org/2001/XMLSchema#string

Marco Taurchini

http://www.w3.org/2001/XMLSchema#string

Stefano Notarangelo

http://www.w3.org/2001/XMLSchema#string

Vito D'alessandro

http://www.w3.org/2001/XMLSchema#string

P2860

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

P304

1281-1288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17425255.2017.1401064

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Graziano

E Maiello

P577

2017-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29095090

http://www.w3.org/2001/XMLSchema#string